1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
ALK Positive and Pfizer Grant Opportunity: Education and Support for ALK+ Lung Cancer is sponsored by Pfizer Inc.. Supports independent medical education projects designed to enhance understanding, confidence, and quality of life for individuals facing an advanced ALK+ NSCLC diagnosis.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
ALK Positive and Pfizer Announce New Grant Opportunity to Improve Education and Support for People Living With Advanced ALK+ Lung Cancer | ALK Positive Lung and Other ALK Positive Cancers Treatment Options for ALK+ Questions to Ask Your Doctor Second Opinion Program Eligible ALK Positive Members can apply for a second opinion from specialists in ALK-positive lung cancer.
Patient & Care Partner Stories Scientific Advisory Board Shop A percentage of all sales of ALK+ Positive apparel will be donated to ALK POSITIVE. ALK Positive and Pfizer Announce New Grant Opportunity to Improve Education and Support for People Living With Advanced ALK+ Lung Cancer We’re proud to partner with Pfizer on a new grant opportunity designed to strengthen education for people diagnosed with advanced ALK-positive lung cancer.
This RFP supports independent projects that help patients and care partners prepare for treatment, recognize side effects early, and access clear, inclusive resources that honor their preferences.
Funding is available for organizations… December 2025 — ALK Positive is proud to announce a new partnership with Pfizer to address a critical gap in patient and caregiver education for those navigating advanced ALK-positive non-small cell lung cancer (NSCLC).
Together, we are launching a Request for Proposals (RFP) to support independent medical education (IME) projects designed to enhance understanding, confidence, and quality of life for individuals facing an ALK+ diagnosis. This collaboration reflects a shared commitment to meeting the real-world needs of patients and care partners — especially as treatment landscapes evolve and targeted therapies continue to transform outcomes.
Full RFP link: Advancing Care for Patients with Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC) People diagnosed with advanced ALK+ NSCLC are often thrust into a complex treatment journey.
ALK inhibitors have dramatically improved outcomes, but patients and families still report uncertainty in several areas: What to expect when starting ALK inhibitor therapy How to recognize early side effects How and when to engage with healthcare teams How to balance treatment with quality of life How to make decisions aligned with personal goals and preferences Education is one of the most powerful tools we can offer.
When people understand their treatment, feel equipped to discuss symptoms, and have access to clear, accessible resources, they are better able to advocate for themselves — and live well. This RFP is designed to fuel creative, high-impact solutions that directly address those needs.
What This Grant Opportunity Supports Organizations are invited to submit proposals for independent projects that advance patient and caregiver education in the ALK+ community. Areas of focus include: 1. Preparing patients and care partners for ALK inhibitor therapy Resources that explain what treatment entails, expected side effects, and how to communicate effectively with care teams.
2. Tools for early side-effect recognition and quality-of-life support Materials that help patients identify symptoms early and make lifestyle adjustments that support overall well-being. 3.
Resources that elevate patient preferences and accessibility Decision aids, multilingual tools, inclusive education models, and approaches that ensure all patients — regardless of background, language, or health literacy — can fully engage in their care.
Proposals may take many forms, such as: Plain-language patient toolkits Digital or interactive learning tools Symptom-preparedness guides Multidisciplinary communication resources Innovative education formats designed with patients in mind (Please note: this opportunity supports independent medical education ; Pfizer and ALK Positive will not be involved in developing, implementing, or conducting funded projects.)
RFP Release Date: December 3, 2025 Application Deadline: February 18, 2026 Geographic Scope: North America, South America, Europe, and Australia Funding: Individual projects up to $100,000 Eligible Applicants: Academic institutions, healthcare systems, patient advocacy organizations, medical societies, and medical education companies Full eligibility criteria, submission instructions, and proposal requirements are included in the RFP linked here.
As a patient-founded organization, ALK Positive has always believed in the power of knowledge. Education is not simply information — it is empowerment, clarity, and hope. We are grateful to partner with Pfizer in offering this meaningful opportunity to organizations that share this mission.
By supporting independent educational projects, we aim to ensure that people living with ALK+ lung cancer — and the families walking beside them — have the tools, confidence, and understanding they need from the very start of their treatment journey. We look forward to seeing innovative proposals that uplift and strengthen our community. Refer to complete details in the full RFP document .
If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein ( amanda. j. stein@pfizer.
com ).
ALK Positive Grants Support Dr. Alice Shaw’s Pioneering ALK-Positive Lung Cancer Research ALK Positive and the American Association for Cancer Research (AACR) partner to fund a two-year AACR-ALK Positive Lung Cancer Research Fellowship ALK Positive Inc. Appoints Dr. Ken Culver as Executive Director & Medical Director to Lead Research and Patient Advocacy Initiatives Dedicated to improving the lives of ALK Positive patients worldwide.
Patient & Care Partner Stories About Us Learn more about the ALK+ Positive organization. 6595 ROSWELL RD, STE. G2310, ATLANTA, GA 30328 The content on the ALK Positive website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.
Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.
Key questions and narrative sections extracted from the solicitation.
Goals and Objectives: Briefly state the overall goal of the project. List the objectives you plan to meet in terms of learning and expected outcomes.
Assessment of Need for the Project: Describe your needs assessment including how you identify gaps between patients' current knowledge, skills, and behaviors and what they need to manage their health effectively.
Target Audience: Describe the primary audience(s) targeted for this project and who will directly benefit from the project outcomes.
Project Design and Methods: Describe the planned project, the educational approach, and how the methods address the established need.
Innovation: Explain measures taken to assure originality and how the project builds upon existing work or pilot projects.
Evaluation and Outcomes: Describe how your organization will determine if the gap was addressed, identify data sources, describe data collection/analysis methods, and quantify expected change.
Dissemination Plan: Describe how the project may have extended benefit beyond the grant, including publicly available tools/resources and broad dissemination of outcomes.
Anticipated Project Timeline: Provide anticipated timeline including start/end dates.
Organization Detail: Describe the attributes of institutions/organizations that will support the project and articulate specific roles of each partner.
Budget Detail: Include budget narrative detailing line items and calculations.
According to the current listing, eligibility includes: Academic institutions, healthcare systems, patient advocacy organizations, professional organizations/medical societies, medical education companies. Must be based in eligible geographic regions. Only organizations eligible, not individuals or physician-owned practices. Confirm the full requirements in the official notice before applying.
The current listing shows $100,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was February 18, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
ALK Positive and Pfizer Grant Opportunity: Education and Support for ALK+ Lung Cancer is funded by Pfizer Inc.. Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The solicitation lists one required document: Project Proposal (15-page limit, excluding references). Check the official notice for formatting and page-limit rules.